Analytics, not advice. Rankings and scores describe past performance and are not recommendations.
Uncategorised
Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option
Nippon India Mutual Fund
Latest NAV
₹628.8418
as of 22 Jul 2026
AUM
—
Expense ratio
—
Inception
—
Trailing returns
Annualised returns to the latest NAV. Refreshed nightly.
1M
2.33%
3M
—
6M
—
1Y
—
3Y CAGR
—
5Y CAGR
—
Since incep.
3.28%
NAV history
Zoom and pan · ranges from 1M to since-inception.
Rolling returns
Every 30-day step. The true distribution, not cherry-picked.
Rank history
Percentile within category over the last 2 years.
FundScore components
Pro-only breakdown of consistency, recency, and volatility scores.
Upgrade to Pro to see the raw drivers behind this scheme's FundScore label.
Pro
Stock holdings
Latest portfolio disclosure for this scheme. Snapshot as of 31 May 2026.
Sun Pharmaceutical Industries Limited
equity
13.35%
Lupin Limited
equity
7.31%
Dr. Reddy's Laboratories Limited
equity
6.72%
Cipla Limited
equity
6.16%
Divi's Laboratories Limited
equity
5.80%
Apollo Hospitals Enterprise Limited
equity
5.20%
Mankind Pharma Limited
equity
3.94%
MedPlus Health Services Limited
equity
3.68%
Sai Life Sciences Limited
equity
3.43%
Vijaya Diagnostic Centre Limited
equity
3.21%
Ajanta Pharma Limited
equity
3.21%
Max Healthcare Institute Limited
equity
2.97%
Thyrocare Technologies Limited
equity
2.56%
IPCA Laboratories Limited
equity
2.41%
GlaxoSmithKline Pharmaceuticals Limited
equity
2.34%
Aurobindo Pharma Limited
equity
2.32%
Abbott India Limited
equity
2.31%
Gland Pharma Limited
equity
2.09%
Alkem Laboratories Limited
equity
2.06%
Dr. Lal Path Labs Limited
equity
1.90%
Narayana Hrudayalaya Limited
equity
1.81%
Syngene International Limited
equity
1.79%
Pfizer Limited
equity
1.69%
Emcure Pharmaceuticals Limited
equity
1.47%
Suraksha Diagnostic Limited
equity
1.29%
Fortis Healthcare Limited
equity
1.19%
Sanofi Consumer Healthcare India Limited
equity
1.14%
Anthem Biosciences Limited
equity
0.93%
Akums Drugs and Pharmaceuticals Limited
equity
0.92%
Sanofi India Limited
equity
0.83%